Jury is still out on antibody cocktail therapy for covid
Jury is still out on antibody cocktail therapy for covid
BySridhar VivanSridhar Vivan / Jun 2, 2021, 06:00 IST#2021-06-02T06:00:00+05:30
Not all experts are equally enthusiastic about use of a mix of
monoclonal antibodies to treat the infection
There is a debate among health experts over the usage of an antibody cocktail therapy, that had gained fame after then US president
Donald Trump was said to have been administered when he got covid. As a few hospitals in the country have begun using this therapy, there is not much consensus over its effectiveness.
Image used for representational purpose only
BENGALURU: At least eight Covid-19 patients in the city have received a monoclonal antibody cocktail called Casirivimab and Imdevimab. The new drug, which comes in the form of two doses of Rs 60,000 each, offers hope to comorbid patients who have mild to moderate coronavirus infection but face higher risk of developing complications.
Of the eight, two got the drug at St John’s Medical College Hospital on Tuesday. The two men, aged 52 and 38, had undergone a kidney transplant earlier, and have been given the dose to prevent their mild symptoms from turning into a severe infection.